Market Place
Sourcing Support
Akeso Phase 3 Study Shows Positive Results In Cervical Cancer
16 Oct 2024 //
PR NEWSWIRE
Akeso Secures $250M USD For Global Expansion
13 Oct 2024 //
PR NEWSWIRE
Akeso`s Cadonilimab Receives Approval For 1st-Line Gastric Cancer
30 Sep 2024 //
PR NEWSWIRE
Akeso, Summit`s PD-1 Bispecific Outperforms Keytruda In Lung Cancer
09 Sep 2024 //
FIERCE PHARMA
Akeso Reports 2024 First Half Results, Advancing IO Bispecifics
28 Aug 2024 //
PR NEWSWIRE
Ivonescimab Gets Priority Review For First-Line NSCLC Treatment In China
14 Aug 2024 //
PR NEWSWIRE
Two Ivonescimab Results For NSCLC To Be Presented At WCLC 2024
12 Aug 2024 //
PR NEWSWIRE
First Patient Enrolled In US Phase 2 Trial Of Ligufalimab Combo
05 Aug 2024 //
PR NEWSWIRE
NMPA Accepts Akeso`s sBLA For Ivonescimab In 1L PD-L1 Positive NSCLC
29 Jul 2024 //
PR NEWSWIRE
Merck CMO talks Akeso, Summit`s Keytruda head-to-head win
04 Jun 2024 //
FIERCE PHARMA
Akeso`s Cadonilimab Plus Chemotherapy for Gastric Cancer Presented at 2024 AACR
08 Apr 2024 //
PR NEWSWIRE
Akeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab
06 Mar 2024 //
PR NEWSWIRE
Akeso Presented Promising Results of Cadonilimab and Lenvatinib
23 Jan 2024 //
PR NEWSWIRE
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference
08 Jan 2024 //
PR NEWSWIRE
Supplemental New Drug Application for Akeso`s Cadonilimab Accepted by NMPA
05 Jan 2024 //
PR NEWSWIRE
Akeso Published Results from CD47 Antibody Ligufalimab at ASH 2023
15 Dec 2023 //
PR NEWSWIRE
Results of three trials on cadonilimab, and HCC neoadjuvant therapy published
05 Dec 2023 //
PR NEWSWIRE
Akeso invests RMB 850 M to establish Shanghai Global R&D Centre
30 Nov 2023 //
BIOSPECTRUM ASIA
Akeso Launches Construction of Shanghai Global R&D Center
28 Nov 2023 //
PR NEWSWIRE
Cadonilimab Met Primary Endpoint of Progression-Free Survival in Ph III Trial
27 Nov 2023 //
PR NEWSWIRE
Akeso`s bispecific notches ph. 3 victory against gastric cancer
08 Nov 2023 //
FIERCE BIOTECH
Ivonescimab`s Mechanism of Action Highlighting Binding to be Featured
02 Nov 2023 //
PR NEWSWIRE
JTO Published Results of Ivonescimab as First- or Second-line Therapy for NSCLC
30 Oct 2023 //
PR NEWSWIRE
Phase Ib/II Results of Akeso`s PD-1/CTLA-4 Bispecific Antibody Published
24 Oct 2023 //
PR NEWSWIRE
Phase 1a/1b Study Results of Akeso`s PD-1/CTLA-4 Bispecific Antibody Published
19 Oct 2023 //
PR NEWSWIRE
Akeso Announced The Lancet Oncology Publishes Promising Results from Cadonilimab
12 Oct 2023 //
PR NEWSWIRE
Akeso Announced FDA Clearance of IND for CD47 Monoclonal Antibody (AK117)
27 Sep 2023 //
PR NEWSWIRE
Akeso Announced Completion of Patient Enrollment in Phase 3 Trial of Ivonescimab
29 Aug 2023 //
PR NEWSWIRE
Akeso Announced 2023 Interim Results: 1st Profit, Growing Sales of PD-1/CTLA-4
29 Aug 2023 //
PR NEWSWIRE
Akeso Announced that Ivonescimab Granted Priority Review of NDA by China NMPA
25 Aug 2023 //
PR NEWSWIRE
Akeso Announced NDA Acceptance of IL-12/lL-23 Monoclonal Antibody Ebdarokimab
24 Aug 2023 //
PR NEWSWIRE
Akeso Announced First Patient Dosed in PIII of Ivonescimab versus Tislelizumab
18 Aug 2023 //
PR NEWSWIRE
NMPA accepted Akeso`s ebronucimab (PCSK9) marketing application
01 Jun 2023 //
PR NEWSWIRE
Specialised signs partnership agreement with Akeso Inc. and CTTQ-Akeso
11 Apr 2023 //
PR NEWSWIRE
Akeso Reported 2022 Annual Results
15 Mar 2023 //
PR NEWSWIRE
Patient Enrollment Completed for PIII Trial of Akeso`s Cadonilimab
14 Mar 2023 //
PR NEWSWIRE
Summit Closes Deal with Akeso to In-License Innovative Bispecific Antibody
20 Jan 2023 //
BUSINESSWIRE
China NMPA Approved for First-line Treatment of Metastatic Squamous NSCLC
15 Jan 2023 //
PRESS RELEASE
Summit bets $5B that Akeso’s bispecific will reach cancer peak
07 Dec 2022 //
FIERCEBIOTECH
Akeso concludes subject enrolment in Phase III NSCLC antibody trial
07 Nov 2022 //
CLINICALTRIALSARENA
Akeso Announces Oral Presentation of Ivonescimab (PD-1/VEGF Bi-Specific)
30 Oct 2022 //
PRNEWSWIRE
Akeso receives NMPA approval for PhIb/II trial of Ivonescimab & drebuxelimab
18 Oct 2022 //
PHARMABIZ
Akeso`s Cadonilimab included in the 2022 CSCO Guidelines
16 Oct 2022 //
PRNEWSWIRE
Akeso Is Developing Therapies Based on PD-1 BsAbs PD-1/VEGF with CD73
16 Oct 2022 //
PRNEWSWIRE
TIGIT/TGF-? fusion protein of Akeso demonstrated results published at ESMO
13 Sep 2022 //
PRNEWSWIRE
First approval of Cadonilimab published in a peer-reviewed medical journal
26 Aug 2022 //
PRNEWSWIRE
Akeso`s Cadonilimab to Treat Cancer, Approved for Marketing in China
29 Jun 2022 //
PRNEWSWIRE
Akeso announces oral presentation on promising clinical data of Cadonilimab
05 Jun 2022 //
PRNEWSWIRE
Akeso releases promising data of Ivonescimab for advanced NSCLC at ASCO 2022
05 Jun 2022 //
PRNEWSWIRE
Akeso Appoints Steven A. Porcelli, MD, to Scientific Advisor Board
17 May 2022 //
GLOBENEWSWIRE
Akeso Publishes Preclinical Results of AK129 at AACR
14 Apr 2022 //
PRNEWSWIRE
Akeso Publishes Preclinical Results of TIGIT MAb, AK127 at AACR
13 Apr 2022 //
PRNEWSWIRE
Akeso Publishes Preclinical Results of AK131 at AACR
13 Apr 2022 //
PRNEWSWIRE
Akeso Reported 2021 Annual Results
01 Apr 2022 //
PRNEWSWIRE
Akeso Announces IND Approval from China NMPA for Phase II Trial of Cadonilimab
07 Mar 2022 //
PRNEWSWIRE
Akeso`s NGF Monoclonal Antibody Approved To Initiate Clinical Trial In Pain
10 Feb 2022 //
PRNEWSWIRE
Akeso`s Ligufalimab, Ivonescimab Obtained Approval To Initiate A Phase II Trial
31 Jan 2022 //
ASIAONE
Akeso gets approval for Phase 1b/2 trial of Cadonilimab+Ivonescimab in NSCLC
06 Jan 2022 //
PRNEWSWIRE
Akeso Acquires Industrial Medical Group
04 Jan 2022 //
BUSINESSWIRE
